173 related articles for article (PubMed ID: 35453899)
1. First-in-Human Study of [
Clausen MM; Carlsen EA; Christensen C; Madsen J; Brandt-Larsen M; Klausen TL; Holm S; Loft A; Berthelsen AK; Kroman N; Knigge U; Kjaer A
Diagnostics (Basel); 2022 Mar; 12(4):. PubMed ID: 35453899
[TBL] [Abstract][Full Text] [Related]
2. Prospective Phase II Trial of [
Carlsen EA; Loft M; Loft A; Czyzewska D; Andreassen M; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2023 Feb; 64(2):252-259. PubMed ID: 35981899
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors.
Oxboel J; Brandt-Larsen M; Schjoeth-Eskesen C; Myschetzky R; El-Ali HH; Madsen J; Kjaer A
Nucl Med Biol; 2014 Mar; 41(3):259-67. PubMed ID: 24417983
[TBL] [Abstract][Full Text] [Related]
4. [(68)Ga]NODAGA-RGD - Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis.
Haubner R; Finkenstedt A; Stegmayr A; Rangger C; Decristoforo C; Zoller H; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2005-13. PubMed ID: 27164900
[TBL] [Abstract][Full Text] [Related]
5. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of
Zhu W; Cheng Y; Jia R; Zhao H; Bai C; Xu J; Yao S; Huo L
J Nucl Med; 2021 Oct; 62(10):1398-1405. PubMed ID: 33579804
[No Abstract] [Full Text] [Related]
6. 68Ga-NODAGA-RGDyK for αvβ3 integrin PET imaging. Preclinical investigation and dosimetry.
Buchegger F; Viertl D; Baechler S; Dunet V; Kosinski M; Poitry-Yamate C; Rüegg C; Prior JO
Nuklearmedizin; 2011; 50(6):225-33. PubMed ID: 21989840
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of an Integrin α
Gai Y; Jiang Y; Long Y; Sun L; Liu Q; Qin C; Zhang Y; Zeng D; Lan X
Mol Pharm; 2020 Jan; 17(1):349-358. PubMed ID: 31829615
[TBL] [Abstract][Full Text] [Related]
8. First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.
Baum RP; Kulkarni HR; Müller D; Satz S; Danthi N; Kim YS; Brechbiel MW
Cancer Biother Radiopharm; 2015 May; 30(4):152-9. PubMed ID: 25945808
[TBL] [Abstract][Full Text] [Related]
9. First in-human radiation dosimetry of
Gnesin S; Mitsakis P; Cicone F; Deshayes E; Dunet V; Gallino AF; Kosinski M; Baechler S; Buchegger F; Viertl D; Prior JO
EJNMMI Res; 2017 Dec; 7(1):43. PubMed ID: 28523582
[TBL] [Abstract][Full Text] [Related]
10. Safety, Dosimetry, and Tumor Detection Ability of
Skovgaard D; Persson M; Brandt-Larsen M; Christensen C; Madsen J; Klausen TL; Holm S; Andersen FL; Loft A; Berthelsen AK; Pappot H; Brasso K; Kroman N; Højgaard L; Kjaer A
J Nucl Med; 2017 Mar; 58(3):379-386. PubMed ID: 27609788
[TBL] [Abstract][Full Text] [Related]
11. Safety, Biodistribution, and Radiation Dosimetry of
Nicolas GP; Beykan S; Bouterfa H; Kaufmann J; Bauman A; Lassmann M; Reubi JC; Rivier JEF; Maecke HR; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
[TBL] [Abstract][Full Text] [Related]
12. (64)Cu-NODAGA-c(RGDyK) Is a Promising New Angiogenesis PET Tracer: Correlation between Tumor Uptake and Integrin α(V)β(3) Expression in Human Neuroendocrine Tumor Xenografts.
Oxboel J; Schjoeth-Eskesen C; El-Ali HH; Madsen J; Kjaer A
Int J Mol Imaging; 2012; 2012():379807. PubMed ID: 23091717
[TBL] [Abstract][Full Text] [Related]
13. Imaging of α
Grönman M; Tarkia M; Kiviniemi T; Halonen P; Kuivanen A; Savunen T; Tolvanen T; Teuho J; Käkelä M; Metsälä O; Pietilä M; Saukko P; Ylä-Herttuala S; Knuuti J; Roivainen A; Saraste A
J Transl Med; 2017 Jun; 15(1):144. PubMed ID: 28629432
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of [
Jahandideh A; Ståhle M; Virta J; Li XG; Liljenbäck H; Moisio O; Knuuti J; Roivainen A; Saraste A
Front Med (Lausanne); 2021; 8():783596. PubMed ID: 34977085
[TBL] [Abstract][Full Text] [Related]
15. [68Ga]NODAGA-RGD for imaging αvβ3 integrin expression.
Knetsch PA; Petrik M; Griessinger CM; Rangger C; Fani M; Kesenheimer C; von Guggenberg E; Pichler BJ; Virgolini I; Decristoforo C; Haubner R
Eur J Nucl Med Mol Imaging; 2011 Jul; 38(7):1303-12. PubMed ID: 21487838
[TBL] [Abstract][Full Text] [Related]
16. In Vivo Characterization of 4
Lobeek D; Franssen GM; Ma MT; Wester HJ; Decristoforo C; Oyen WJG; Boerman OC; Terry SYA; Rijpkema M
J Nucl Med; 2018 Aug; 59(8):1296-1301. PubMed ID: 29626124
[TBL] [Abstract][Full Text] [Related]
17. 68Ga-NODAGA-RGD is a suitable substitute for (18)F-Galacto-RGD and can be produced with high specific activity in a cGMP/GRP compliant automated process.
Pohle K; Notni J; Bussemer J; Kessler H; Schwaiger M; Beer AJ
Nucl Med Biol; 2012 Aug; 39(6):777-84. PubMed ID: 22444238
[TBL] [Abstract][Full Text] [Related]
18. Imaging of Myocardial α
Nammas W; Paunonen C; Teuho J; Siekkinen R; Luoto P; Käkelä M; Hietanen A; Viljanen T; Dietz M; Prior JO; Li XG; Roivainen A; Knuuti J; Saraste A
J Nucl Med; 2024 Jan; 65(1):132-138. PubMed ID: 37973184
[TBL] [Abstract][Full Text] [Related]
19. Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD.
Zhang J; Niu G; Lang L; Li F; Fan X; Yan X; Yao S; Yan W; Huo L; Chen L; Li Z; Zhu Z; Chen X
J Nucl Med; 2017 Feb; 58(2):228-234. PubMed ID: 27493267
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]